Generic Vabomere Availability
Last updated on Sep 11, 2024.
Vabomere is a brand name of meropenem/vaborbactam, approved by the FDA in the following formulation(s):
VABOMERE (meropenem; vaborbactam - powder;intravenous)
-
Manufacturer: REMPEX
Approval date: August 29, 2017
Strength(s): 1GM/VIAL;1GM/VIAL [RLD]
Has a generic version of Vabomere been approved?
No. There is currently no therapeutically equivalent version of Vabomere available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vabomere. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Patent 10,172,874
Issued: January 8, 2019
Inventor(s): Hirst Gavin & Reddy Raja & Hecker Scott & Totrov Maxim & Griffith David C. & Rodny Olga & Dudley Michael N. & Boyer Serge
Assignee(s): REMPEX PHARMACEUTICALS, INC.Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
Patent expiration dates:
- August 8, 2031✓
- August 8, 2031
-
Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Patent 10,183,034
Issued: January 22, 2019
Inventor(s): Hirst Gavin & Reddy Raja & Hecker Scott & Totrov Maxim & Griffith David C. & Rodny Olga & Dudley Michael N. & Boyer Serge
Assignee(s): Rempex Pharmaceuticals, Inc.Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
Patent expiration dates:
- August 8, 2031✓
- August 8, 2031
-
Cyclic boronic acid ester derivatives and therapeutic uses thereof
Patent 10,561,675
Issued: February 18, 2020
Inventor(s): Griffith David C. & Dudley Michael N. & Rodny Olga
Assignee(s): REMPEX PHARMACEUTICALS, INC.Method of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent such as Biapenem, and the pharmacokinetics studies thereof are provided.
Patent expiration dates:
- August 8, 2031✓
- August 8, 2031
-
Cyclic boronic acid ester derivatives and therapeutic uses thereof
Patent 11,007,206
Issued: May 18, 2021
Inventor(s): Griffith David C. & Dudley Michael N. & Lomovskaya Olga
Assignee(s): MELINTA SUBSIDIARY CORP.Method of treating or ameliorating a bacterial infection comprising administering a composition comprising a cyclic boronic acid ester compound in combination with a carbapenem antibacterial agent such as Biapenem, and the pharmacokinetics studies thereof are provided.
Patent expiration dates:
- August 8, 2031✓
- August 8, 2031
-
Patent 11,376,237
Patent expiration dates:
- April 6, 2039✓
- April 6, 2039
-
Cyclic boronic acid ester derivatives and therapeutic uses thereof
Patent 8,680,136
Issued: March 25, 2014
Inventor(s): Hirst Gavin & Reddy Raja & Hecker Scott & Totrov Maxim & Griffith David C. & Rodny Olga & Dudley Michael N. & Boyer Serge
Assignee(s): Rempex Pharmaceuticals, Inc.Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.
Patent expiration dates:
- August 29, 2031✓✓
- August 29, 2031
-
Cyclic boronic acid ester derivatives and therapeutic uses thereof
Patent 9,694,025
Issued: July 4, 2017
Inventor(s): Hirst Gavin & Reddy Raja & Hecker Scott & Totrov Maxim & Griffith David C. & Rodny Olga & Dudley Michael N. & Boyer Serge
Assignee(s): Rempex Pharmaceuticals, Inc.Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.
Patent expiration dates:
- August 8, 2031✓
- August 8, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 29, 2022 - NEW CHEMICAL ENTITY
- August 29, 2027 - GENERATING ANTIBIOTIC INCENTIVES NOW
More about Vabomere (meropenem / vaborbactam)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: carbapenems/beta-lactamase inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.